CFHR1 and complement 3 glomerulopathy: Our data also suggest a novel treatment for C3G in which short 2-O-desulfated heparin oligosaccharides are used to scavenge FHR1 and FHR5, thereby altering the binding of these proteins to the glomerular glycocalyx (Figure 5).